|
Volumn 17, Issue 2, 2010, Pages 358-361
|
Editorial: Why does no one want to perform lymph node dissection anymore?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ALPHA2B INTERFERON;
ADJUVANT THERAPY;
CANCER ADJUVANT THERAPY;
CANCER CONTROL;
CANCER DIAGNOSIS;
CANCER RADIOTHERAPY;
CANCER RECURRENCE;
CANCER STAGING;
CANCER SURGERY;
CANCER SURVIVAL;
CERVICAL LYMPH NODE;
COMORBIDITY;
DECISION MAKING;
DISEASE FREE SURVIVAL;
DRUG MEGADOSE;
EARLY DIAGNOSIS;
EDITORIAL;
HIGH RISK POPULATION;
HUMAN;
LEG;
LYMPH NODE DISSECTION;
LYMPH NODE METASTASIS;
LYMPHADENECTOMY;
LYMPHEDEMA;
MELANOMA;
QUALITY OF LIFE;
RISK BENEFIT ANALYSIS;
SENTINEL LYMPH NODE;
SENTINEL LYMPH NODE BIOPSY;
SURGEON;
SURVIVAL RATE;
TREATMENT REFUSAL;
TUMOR VOLUME;
METASTASIS;
NOTE;
TREATMENT OUTCOME;
HUMANS;
LYMPH NODE EXCISION;
LYMPHATIC METASTASIS;
MELANOMA;
SENTINEL LYMPH NODE BIOPSY;
TREATMENT OUTCOME;
|
EID: 77149140451
PISSN: 10689265
EISSN: 15344681
Source Type: Journal
DOI: 10.1245/s10434-009-0837-2 Document Type: Editorial |
Times cited : (10)
|
References (7)
|